Results 331 to 340 of about 1,162,311 (403)

Retrotransposons are co-opted to activate hematopoietic stem cells and erythropoiesis. [PDF]

Science
Phan J, Chen B, Zhao Z, Allies G, Iannaccone A, Paul A, Cansiz F, Spina A, Leven AS, Gellhaus A, Schadendorf D, Kimmig R, Mettlen M, Tasdogan A, Morrison SJ.   +14 more
europepmc   +1 more source

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio‐Oncology

European Journal of Heart Failure, EarlyView.
Specific characteristics of HFpEF universal definition in cancer patients. Abstract Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown.
Kalliopi Keramida, Teresa Lopez‐Fernandez, Markus S. Anker, Mark C. Petrie, Pietro Ameri, Lisa J. Anderson, Jutta Bergler‐Klein, Anita Deswal, Dimitrios Farmakis, Borja Ibañez, Carolyn S.P. Lam, Ninian N. Lang, Alexander R. Lyon, Mariana Mirabel, Brenda Moura, Walter J. Paulus, Amina Rakisheva, Gianluigi Savarese, Michele Senni, Carlo Gabriele Tocchetti, Marco Metra, Gerasimos Filippatos   +21 more
wiley   +1 more source

Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation. [PDF]

Stem Cell Res Ther
Aljagthmi AA, Abdel-Aziz AK.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Bone marrow niches for hematopoietic stem cells. [PDF]

Hemasphere
Pereira AL, Galli S, Nombela-Arrieta C.
europepmc   +1 more source

Predictive factors for engraftment kinetics of autologous hematopoietic stem cells in children. [PDF]

Hematol Transfus Cell Ther
Andrić B, Vujić D, Šerbić O, Radonjić Z, Simić M, Kuzmanović M.   +5 more
europepmc   +1 more source

Toward immunoprofiling in MDS: A computational study of the bone marrow immune microenvironment

Cytometry Part B: Clinical Cytometry, EarlyView.
Margot F. van Spronsen, Luca L. G. Janssen, Tessa Poolman, Theresia M. Westers, Yvan Saeys, Reina E. Mebius, Arjan A. van de Loosdrecht   +6 more
wiley   +1 more source

Lineage tracing studies suggest that the placenta is not a de novo source of hematopoietic stem cells. [PDF]

PLoS Biol
Chen X, Tober J, Dominguez M, Tang AT, Bockman J, Yang J, Mani S, Lee CN, Chen M, Thillaikumaran T, Mericko-Ishizuka P, Mainigi M, Speck NA, Kahn ML.   +13 more
europepmc   +1 more source

A new double reporter strategy reveals a subset of non-migratory hematopoietic stem cells localized in a dynamic bone marrow niche

Secchi MA, Liu Q, Antón SG, Mai C, Jibril A, Xu J, O’Carroll D, Wilson NK, Kranc KR, Göttgens B, Celso CL, Luis TC.   +11 more
europepmc   +1 more source

Astragaloside IV accelerates hematopoietic reconstruction by improving the AMPK/PGC1α-mediated mitochondrial function in hematopoietic stem cells. [PDF]

Chin Med
Zhang L, Xu W, Zeng Y, Wang L, Luo J, Zhou X, Mei Q, Qin D, Wu A, Wu J, Huang F.   +10 more
europepmc   +1 more source